

---

## Alzecure Pharma - Further Pipeline Advancement Expected

Alzecure Pharma's Q4'20 report (published last week) summarized a year where the company advanced across its pipeline and reported milestones according to plan. Even though we see no major milestones (except a partner deal that serves as a joker for this exciting early-stage biotech) occurring in 2021, it will be equally important to continue steady progress and its transition into a fully-fledged development organization. In this update, we deep-dive onto the news flow investors could expect and go through the key changes we have made that have led to a new Base Case.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Alzecure Pharma - Further Pipeline Advancement Expected**